Comparative Pharmacology
Head-to-head clinical analysis: ALA SCALP versus FLURANDRENOLIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA SCALP versus FLURANDRENOLIDE.
ALA-SCALP vs FLURANDRENOLIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (PpIX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), PpIX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects.
Topical application of a 5% solution to the scalp twice daily.
Apply 0.025% to 0.05% cream or ointment topically to affected area twice daily.
None Documented
None Documented
Clinical Note
moderateFlurandrenolide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Gatifloxacin."
Clinical Note
moderateFlurandrenolide + Rosoxacin
"The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Rosoxacin."
Clinical Note
moderateFlurandrenolide + Levofloxacin
"The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Levofloxacin."
Clinical Note
moderateNot applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
Terminal elimination half-life approximately 18–36 hours; clinical context: prolonged with hepatic impairment; supports once-daily or twice-daily topical dosing.
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Renal (<1% unchanged), biliary/fecal (major route, as metabolites); <1% excreted unchanged in urine.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid
Flurandrenolide + Trovafloxacin
"The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Trovafloxacin."